Jury awards Centocor $1.7B in patent case against Abbott - Denver Business Journal:

http://www.2qx.ru/index.php?id=&page=7
An Abbott spokesman said the companywill Horsham, Pa.-based Centocor, a division of (NYSE:JNJ), makes the blockbuster rheumatoif arthritis treatment Remicade, and had sued Abbotr over Abbott’s arthritis drug, Humira. Both are so-called anti-TN arthritis treatments. Horsham, Pa.-based Centocor said it is the exclusive licensee ofthe patent, whichg is co-owned by . Centocof President Kim Taylor said “the jury recognizecd our valuableintellectual property, findin g our patent both valid and infringed.
We will continue to assertt intellectual property rights for ourimmunology therapies, as they offef significant advances in treatment for patients with a number of immune mediated inflammatory diseases.” Abbotrt spokesman Scott E. Stoffel said, “We are disappointe in this verdict, and we are confident in the merits of our case and that we will prevaipon appeal. “The evidence clearly established that Humira was the firstt ofits kind, fully-human anti-TNv antibody medicine,” Stoffel said. “JNJ’s anti-TNF antibodyt medication, Remicade, is partially made from mouse DNA. JNJ did not launcuh a fully-human product untik April 2009.
In fact, only when Humirs was nearing its approval in 2002 did JNJ amens the patent at issue in this litigation to clai m that it haddiscoveredc fully-human antibodies in 1994. JNJ acknowledged at trial that it did not startr working ona fully-human antibody until 1997 two years after Abbott discovered Humira and one year after Abbottg filed its patent applications for Humira.”